GSK461364A
SIGMA/SML1912 - ≥98% (HPLC)
Synonym: (R)
CAS Number: 929095-18-1
Empirical Formula (Hill Notation): C27H28F3N5O2S
Molecular Weight: 543.60
MDL Number: MFCD12755419
Linear Formula: C27H28F3N5O2S
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C27H28F3N5O2S/c1-17(19 |
| InChI key | ZHJGWYRLJUCMRT-QGZVFWFLSA |
| Quality Level | 100 ![]() |
| SMILES string | CN1CCN(CC2=CC3=C(N=CN3C4= |
| solubility | DMSO: 25 mg/mL, clear |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | A potent, reversible, ATP-competitive, and highly selective polo-like kinase 1 (Plk1) inhibitor with in vitro and in vivo anti-cancer efficacy. |
| Biochem/physiol Actions: | GSK461364 is an imidazotriazine derivate that inhibits polo-like kinase 1 (Plk1) in a potent, reversible, ATP-competitive, and highly selective manner (Kiapp <0.5 nM vs. 0.86 μM for Plk2 and 200 μM for Plk3; ATP Kmapp = 16 μM), exhibiting much reduced or little potency toward a panel of 262 kinases. GSK461364A inhibits the growth of various cancer cultures (IG50 <100 nM) as a result of either growth arrest (cytostasis) or cytotoxicity in vitro and effectively suppresses the expansion of various human tumor exnografts in mice in vivo (25 or 50 mg/kg i.p. q2dx12). |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |

